Persica Pharmaceuticals publishes PK/PD case for PP353 in back pain
Persica Pharmaceuticals has published a pharmacokinetic/pharmacodynamic modelling analysis arguing that variable clinical outcomes across published antibiotic studies in vertebrogenic lumbar back pain (vLBP) are best explained by differences in antibiotic exposure at the disc rather than contradictory biology. The manuscript has been submitted to the European Spine Journal and is currently available on its preprint server.
The London-based clinical-stage company examined both oral and intradiscal antibiotic studies in patients with chronic low back pain and Modic type changes, and found a strong exposure-response relationship across the dataset. In oral antibiotic studies, nominal dose alone accounted for more than 98% of the between-study variability in pain and disability outcomes at 12 months. Across the combined oral and intradiscal dataset, the association between estimated intradiscal antibiotic exposure and clinical improvement was highly significant for both endpoints (p less than 0.001).
Persica contends that PP353, administered directly into the affected intervertebral disc, achieves substantially higher local antibiotic concentrations than is feasible with oral dosing, while avoiding the systemic exposure that accompanies prolonged oral antibiotic regimens.
Scientific rationale
Dr Lloyd Czaplewski, Chief Scientific Officer at Persica, said the analysis "helps to bring clarity to a field that has often been viewed as inconsistent," adding that the published evidence indicates clinical outcomes improve as antibiotic exposure at the disc increases.
The new publication builds on Phase 1b data for PP353 that appeared in The Lancet's eClinicalMedicine in February 2026. That randomised, double-blind, sham-controlled study enrolled 40 participants and reported statistically significant improvements in pain and disability. More than 60% of treated patients achieved a pain reduction of at least 50% at 12 months, and the company reported decreased opioid usage in the treated group. The primary Phase 1b results carry more weight than the modelling analysis published today, though the PK/PD work provides a mechanistic frame for interpreting the broader literature.
PP353 is formulated as a thermosensitive linezolid powder that liquefies at room temperature and increases in viscosity at body temperature once injected, a design intended to limit migration into adjacent tissue. A radio-opaque dye allows image-guided confirmation of placement. Persica is seeking a strategic partner or investor to fund the registrational Phase 3 programme.
Market context and competitive landscape
Vertebrogenic lumbar back pain, characterised by Modic type changes visible on MRI at the vertebral endplate, is estimated to account for roughly 15% of all chronic low back pain cases, representing approximately 10 million patients across the US and European Union. Current standard of care is largely analgesic-based, including opioid therapy, and the field has limited disease-modifying options. That unmet need, and the regulatory and public-health pressure to reduce opioid prescribing, has drawn increasing interest from both academic groups and early-stage companies.
The antibiotic hypothesis for vLBP remains contested in some quarters of the orthopaedic and spine community, where a series of inconsistent trial results over the past decade created scepticism. Persica's modelling argument, that exposure variability rather than biological inconsistency explains the disparate results, is a coherent reframing, but will require validation in a powered registrational trial before it is likely to shift clinical practice. The company has not yet announced a Phase 3 design, timeline, or funding partner, meaning the path from today's publication to market remains long and contingent on securing external capital.